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Abstract
Background: Plasma concentrations of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide
synthase, are raised in patients with chronic vascular disease, causing increased cardiovascular risk and endothelial
dysfunction, but the role of ADMA in acute inflammatory states is less well defined.
Methods and Results: In a prospective longitudinal study in 67 patients with acute sepsis and 31 controls, digital
microvascular reactivity was measured by peripheral arterial tonometry and blood was collected at baseline and 2–4 days
later. Plasma ADMA and L-arginine concentrations were determined by high performance liquid chromatography. Baseline
plasma L-arginine: ADMA ratio was significantly lower in sepsis patients (median [IQR] 63 [45–103]) than in hospital controls
(143 [123–166], p,0.0001) and correlated with microvascular reactivity (r = 0.34, R2 = 0.12, p = 0.02). Baseline plasma ADMA
was independently associated with 28-day mortality (Odds ratio [95% CI] for death in those in the highest quartile
($0.66 mmol/L) = 20.8 [2.2–195.0], p = 0.008), and was independently correlated with severity of organ failure. Increase in
ADMA over time correlated with increase in organ failure and decrease in microvascular reactivity.
Conclusions: Impaired endothelial and microvascular function due to decreased endothelial NO bioavailability is a potential
mechanism linking increased plasma ADMA with organ failure and death in sepsis.
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Introduction
Asymmetric dimethylarginine (ADMA), an endogenous non-
specific nitric oxide synthase (NOS) inhibitor, is associated with
chronic endothelial dysfunction [1] and increased cardiovascular
risk [2], but its role in the setting of acute infections has been less
well characterised.
Severe sepsis (acute infection resulting in organ dysfunction) is
the leading cause of death in intensive care units in the USA [3],
and is increasing in incidence globally [4]. Microvascular and
endothelial dysfunction are key contributors to organ failure and
death in sepsis but the mechanisms linking sepsis with vascular
dysfunction remain incompletely understood [5]. A relative
deficiency of constitutively expressed endothelial nitric oxide
(NO), essential to maintain a quiescent and functional endothe-
lium, may underlie sepsis-associated endothelial and microvascular
dysfunction [6,7]. NO is produced by NOS from its primary
substrate, L-arginine. ADMA competitively inhibits the produc-
tion of NO by NOS and additionally, along with symmetrical
dimethylarginine (SDMA) and L-lysine, competes with L-arginine
for transport across the cell membrane [8]. Hence the L-arginine:
ADMA ratio is considered a better indicator of the availability of
L-arginine to NOS than is plasma L-arginine concentration alone
[9].
Infusion of ADMA in both rats [10] and humans [11] acutely
decreases NO production, resulting in endothelial dysfunction.
Plasma ADMA concentrations are increased in patients with
chronic renal disease [12], hypertension [13], diabetes mellitus
[14] and peripheral vascular disease [15]. Furthermore, ADMA
has been shown to be an independent predictor of cardiovascular
events in patients with existing coronary artery disease [16] and
end-stage renal disease [17].
In contrast, few studies have examined the role of ADMA in
humans with sepsis, and none have reported L-arginine: ADMA
ratios or examined microvascular reactivity in this context. The
few clinical studies that have reported plasma ADMA concentra-
tions during acute infection have had conflicting results
[18,19,20,21]. Using peripheral arterial tonometry, we have
previously shown that digital microvascular reactivity, a measure
of endothelial NO bioavailability [22], is decreased in patients with
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sepsis [7]. However, we did not find a correlation between
concentrations of plasma L-arginine and microvascular reactivity.
We also found that despite an increase in plasma L-arginine
concentrations over time, there was no corresponding improve-
ment in microvascular reactivity. A potential explanation for these
findings in sepsis is competitive inhibition of NOS by ADMA.
We hypothesised that plasma L-arginine: ADMA ratio would be
decreased in sepsis, in proportion to disease severity, and would
correlate with reactive hyperaemia peripheral arterial tonometry
(RH-PAT) index, an in vivo measure of endothelial NO
bioavailability. Furthermore, we hypothesised that increased
plasma ADMA would be associated with mortality.
Methods
Study design and setting
We performed a prospective observational study at a 350-bed
Australian teaching hospital, with an 18-bed mixed intensive care
unit (ICU). Approval was obtained from the Human Research
Ethics Committee of the Menzies School of Health Research and
the Department of Health and Community Services. Written
informed consent was obtained from all participants or next of kin
where necessary.
Participants
The study subjects were adults ($18 years) hospitalised with
sepsis, who were enrolled in a previously-reported study of
microvascular reactivity; more detail of subject recruitment and
study procedures are provided in this paper [7]. Sepsis was defined
as a proven or suspected infection plus at least 2 criteria for the
systemic inflammatory response syndrome (SIRS) present within
the last 4 hours [23]; these include tachycardia (heart rate.90
beats per minute), tachypnoea (respiratory rate .20 breaths/
minute), abnormal temperature (body temperature .38uC or
,36uC), and abnormal white blood cell count (,4,000 cells/ml or
.12,000 cells/ml or .10% band forms). Septic patients were
eligible for enrolment within 24 hours of their admission to the
ICU, or within 36 hours of admission to the ward. Control
subjects were adults recruited from hospitalised patients with no
clinical or laboratory evidence of inflammation or infection, and
who had not met SIRS criteria within the last 30 days. Septic
patients were classified as septic shock, or sepsis without shock.
Septic shock was defined at the time of enrolment as systolic blood
pressure ,90 mmHg or a reduction of $40 mmHg from baseline
despite adequate fluid resuscitation, or the need for vasopressors to
maintain these targets [23]. Disease severity was assessed by the
Acute Physiology and Chronic Health Evaluation (APACHE) II
score and organ failure was determined using the Sequential
Organ Failure Assessment (SOFA) score [24].
Laboratory assays
Blood from arterial lines if present, or venepuncture if not, was
collected in lithium heparin tubes at baseline and 2–4 days later,
and plasma was separated and stored at 270uC within 2 hours of
blood collection. Control patients had blood collected at baseline
only.
ADMA and SDMA were measured by reverse phase HPLC
with simultaneous fluorescence and UV-visible detection, as
previously described [25]. The method precision, represented by
percent relative standard deviation was 2.0% for ADMA and
2.3% for SDMA. Method accuracy measured by percent spike
recovery was 98% for ADMA and 99% for SDMA. Arginine was
measured using a method modified from van Wandelen and
Cohen [26]. Angiopoietin-2 (Ang-2) and intracellular adhesion
molecule-1 (ICAM-1) were measured by ELISA (R&D systems).
IL-6 and TNFa were measured by flow cytometry using a cytokine
bead array (BD Biosciences, CA, USA).
Measurement of microvascular reactivity
Microvascular reactivity was measured at the bedside by RH-
PAT (Itamar Medical, Caesarea, Israel), a non-invasive method of
assessing endothelial function [27–28] which is at least 50%
dependent on endothelial NO production [22]. Peripheral arterial
tonometry (PAT) was measured in a fingertip before and after a 5-
minute ischemic stress at the forearm, generating an RH-PAT
index, normalized to the control arm, as previously reported [7].
Statistical methods
Continuous variables were compared using Mann Whitney U test,
and categorical variables using Fisher’s exact test. Correlates with
Table 1. Baseline characteristics.
Septic Shock Sepsis without shock Controls p valuea
n 20 47 31
Ageb 51.5(12.0) 52.5 (14.4) 45.4 (12.7) NS
Malec 11 (55) 30 (63) 24 (75) NS
Diabeticc 6 (30) 13 (27) 10 (31) NS
Smokerc 8 (40) 22 (46) 14 (44) NS
IHDc 4 (20) 8 (17) 4 (13) NS
Hypertensionc 5 (25) 17 (35) 9 (28) NS
Hyperlipidemiac 4 (20) 11 (22) 11 (34) NS
Chronic renal diseasec 4 (20) 4 (8) 3 (10) NS
APACHE II scored 20.0 (16–23) 10.0 (6–16) ,0.0001
SOFA scored 6 (3–9) 2.0 (0.5–4.0) ,0.0001
a – by Chi2 test for difference between all 3 groups.
b – Mean (sd).
c – n (%).
d – Median (Interquartile range).
doi:10.1371/journal.pone.0017260.t001
ADMA in Sepsis
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baseline ADMA and arginine:ADMA ratio were determined using
Spearman’s coefficient for univariate analysis. Day 2 values were
compared with baseline values using pairedWilcoxon signed-rank test.
In an a priori analytical plan, the relationship between baseline ADMA
and mortality among sepsis patients was examined using logistic
regression, with ADMA divided into quartiles as previously described
[29]. To examine longitudinal correlations, linear mixed-effects models
were used. A 2-sided p-value of ,0.05 was considered significant. All
analyses were performed using Intercooled Stata 10 (Statacorp, Texas).
Results
There were 20 subjects with septic shock, 47 with sepsis without
shock and 31 controls. The three groups were well-matched in
terms of age, sex and known associations with chronically raised
ADMA (Table 1).
Arginine:ADMA ratio and disease severity
Baseline plasma L-arginine: ADMA ratio was significantly lower
in sepsis patients (median [IQR] 63 [45–103]) than in hospital
controls (143 [123–166], p,0.0001) (Table 2). Furthermore, septic
shock patients had significantly lower L-arginine: ADMA ratio
(median [IQR] 43 [34–73]) than sepsis patients without shock (91
[56–108], p,0.0001) (Figure 1a). The plasma L-arginine: ADMA
ratio inversely correlated with severity of illness as measured by
APACHE II score (r=20.4, R2=0.16, p=0.003) and organ failure
as measured by SOFA score (r=20.5, R2=0.25, p=0.0001).
ADMA, disease severity and mortality
The median [IQR] plasma concentration of ADMA was
significantly higher in septic shock patients (0.64 [0.54–0.85] mM)
than sepsis patients without shock (0.47 [0.38–0.57] mM) (p=0.008)
(Table 2) and correlated with SOFA score (r =0.45, R2=0.20,
p,0.001). Six of 67 sepsis patients (9%) had died by day 28 of follow-
up, 5 of whom were in the septic shock subgroup. Median [IQR]
baseline ADMA was approximately twice as high in those who died
(1.07 [0.75–1.31]) as in survivors (0.51 [0.39–0.61]), p=0.001. Sepsis
patients with a baseline plasma ADMA concentration in the highest
quartile ($0.66 mmol/L) had an odds ratio for death of 20.8 (95%CI
2.2–195.0, p=0.008). In a multivariate model incorporating SOFA
score, age, gender, creatinine and IL-6 concentration, baseline
ADMA was the only significant predictor of death (p=0.04).
SDMA, renal function and disease severity
SDMA was highest in septic shock, intermediate in sepsis
without shock and lowest in controls (Table 2). Predominantly
renally excreted [30], SDMA correlated strongly with serum
creatinine (r = 0.70, R2= 0.49, p,0.001), whereas ADMA did not
(r = 0.16, R2= 0.03, p =NS). On univariate analysis, sepsis
patients with a plasma SDMA concentration in the highest
quartile ($1.30 mmol/L) had an odds ratio for death of 8.12 (95%
CI 1.33–50.0), however this became insignificant on controlling
for renal function.
Arginine, ADMA and microvascular reactivity
There was a modest but significant correlation between baseline
L-arginine: ADMA ratio and NO-dependent microvascular
reactivity as measured by RH-PAT (figures 1a and 1b) both
on univariate analysis (r = 0.34, R2= 0.12, p = 0.02), and in a
multivariate linear regression model adjusting for serum creatinine
(Wald p-value for L-arginine: ADMA ratio = 0.03). The L-
arginine: ADMA ratio was significantly lower in sepsis patients
who required vasopressors (median [IQR] = 42 [32–55])
compared to those who did not (74 [54–108], p = 0.002). Baseline
plasma ADMA concentration correlated with markers of endo-
thelial activation including Ang-2 (r = 0.45, R2= 0.20, p = 0.0002)
and ICAM-1 (r = 0.47, R2= 0.22, p = 0.0001). This relationship
persisted after controlling for disease severity (using APACHE II
score) in a multivariate analysis.
Over the first 2–4 days of follow up, plasma ADMA increased in
the sepsis patients (0.53 to 0.64, p= 0.002) (Table 3), and also in
the septic shock subgroup (0.64 to 0.85, p = 0.03). Plasma L-
arginine concentrations also increased, but due to the increase in
ADMA, there was no significant change in the L-arginine: ADMA
ratio. In a mixed effects linear regression model examining change
from baseline to day 2–4, increase in ADMA over time
Table 2. Plasma asymmetric dimethylarginine and related variables at time of initial measurement.








n 67 20 47 31
Plasma ADMA(mmol/L)a 0.52 (0.39–0.65) 0.64 (0.54–0.85) 0.47 (0.38–0.57) 0.57 (0.50–0.62) 0.10 0.09
Plasma L-arginine (mmol/L)a,b 35.5 (27.3–51.2) 31.0 (23.7–40.4) 38.1 (29.4–51.7) 81.8 (68.9–91.3) ,0.001 ,0.001
Plasma L-arginine/ADMA ratioa,b 63.2 (45.3–103.4) 43.4(33.6–73.3) 91.4 (55.5–108.3) 142.9 (123.0–165.7) ,0.001 ,0.001
Plasma SDMA(mmol/L)a 0.66 (0.50–1.29) 1.05 (0.77–1.45) 0.56 (0.45–0.80) 0.47 (0.43–0.65) 0.002 ,0.001
Plasma lysine(mmol/L)a 128 (100–171) 129 (90–190) 128 (104–162) 184 (157–216) ,0.001 0.006
Receiving mechanical ventilationc 14 (21) 9 (47) 5 (26) - - -
RH-PAT indexd 1.70 (0.47) 1.47 (0.40) 1.78 (0.47) 2.05 (0.46) 0.001 ,0.001
Plasma Interleukin 6 (pg/ml)a 223 (76.6–563) 885 (298–2412) 148 (46.0–322) 4.7 (2.2–9.5) ,0.001 ,0.001
White blood cell counta 15.2 (10.1–20.2) 17.5 (11.0–27.8) 15.2 (9.1–17.8) 7.7 (5.7–9.0) ,0.001 ,0.001
C-reactive proteina 180 (87.3–259) 202 (126–297) 143(84–259) 7 (4–22) ,0.001 ,0.001
a. median (Interquartile range);
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significantly correlated with increase in SOFA score (p,0.001)
and decrease in RH-PAT index (p= 0.03), but not with change in
IL-6 or CRP. It also correlated with increase in the liver (p,0.001)
but not the renal (p = 0.09) components of the SOFA score.
Discussion
The plasma L-arginine: ADMA ratio is significantly reduced in
sepsis, in proportion to disease severity. Plasma ADMA concen-
tration correlates with the degree of organ failure and predicts
mortality in patients with sepsis. Increase in ADMA over time is
associated with worsening microvascular reactivity and organ
dysfunction. Our results suggest a possible mechanism underlying
these associations: impairment of microvascular function due to
inhibition of endothelial NO production by ADMA.
Decreased L-arginine: ADMA ratio may contribute to organ
failure in sepsis by reducing microvascular reactivity. Impaired
microvascular and endothelial function have been shown to be
important contributors to organ dysfunction and death in animals
and humans with sepsis [31]. ADMA causes both acute [11] and
chronic [2] endothelial dysfunction by inhibiting NOS and
decreasing endothelial NO bioavailability. The L-arginine:
ADMA ratio is a marker of the availability of L-arginine to
NOS [9]. In severe malaria, plasma ADMA is increased and is
associated with endothelial dysfunction and reduced exhaled nitric
oxide [32]. In this study we found that baseline L-arginine: ADMA
ratio, but not arginine or ADMA alone, correlated with
endothelial nitric oxide dependent microvascular reactivity.
Furthermore, plasma ADMA concentrations correlated with
increased plasma concentrations of Ang-2 and ICAM-1, both of
which are associated with reduced endothelial nitric oxide
bioavailablity [7,33,34]. Together, these findings suggest that a
decreased L-arginine: ADMA ratio reduces endothelial nitric
oxide bioavailability and thus impairs microvascular reactivity in
sepsis. This may provide a mechanistic explanation for the
observed association of plasma ADMA concentrations with organ
failure and death in this and other studies [20,29]. However,
although significant, this association was not strong and further
work is needed to confirm this preliminary observation.
A recent small study in human volunteers injected with
lipopolysaccharide also found an acute increase in plasma ADMA
and decrease in NO-dependant vasodilatation, but did not find a
correlation between NO-dependant vasodilatation and L-argini-
ne:ADMA ratio [35]. These differing findings may be due to the
fact that in Engelberger’s study, the sample size (n = 7) was too
small to detect such a correlation. In addition, sepsis is a highly
complex pathophysiological state, and the findings from sepsis
models may be difficult to apply to clinical sepsis.
The increase in plasma ADMA concentrations over time
observed in this study agrees with the findings of another recent
observational study in septic humans [21]. This increase may in
part explain the lack of significant improvement in microvascular
reactivity as patients recover [7], despite an increase in plasma L-
arginine. This may be because the L-arginine: ADMA ratio (and
Figure 1. Ratio of L-arginine to asymmetric dimethylarginine in
baseline plasma samples, according to disease category,
compared with baseline microvascular reactivity according to
disease category. Panel A shows plasma arginine: ADMA ratio and
panel B shows reactive hyperaemia peripheral arterial tonometry index.
P values represent comparisons between groups. Solid circles represent
individual sepsis subjects and solid triangles represent individual
control subjects. Horizontal lines represent median group values, and
error bars represent interquartile range. In panel B, solid circles
represent mean group values for sepsis subjects, and the solid triangle
for control subjects. Error bars represent standard error of the mean.
doi:10.1371/journal.pone.0017260.g001
Table 3. Longitudinal results in subjects with sepsis.
Day 0 Day 2 P Day 0 to 2
n 67 47
ADMA 0.53 (0.39–0.66) 0.64 (0.51–0.78) 0.002
L-arginine 35.5 (27.3–51.2) 47.2 (30.8–58.1) 0.03
L-arginine: ADMA
ratio
63.2 (45.3–103.4) 63.0 (41.7–108.0) NS
RH-PAT index 1.70 (1.57–1.82) 1.81 (1.65–1.96) NS
SDMA 0.66 (0.50–1.30) 0.71 (0.47–1.36) NS
IL-6 223 (78.2–530) 54.5 (16.1–201) ,0.001
SOFA score 3 (1–7) 2 (1–7) 0.04
Note: ADMA=Asymmetric dimethylarginine. RH-PAT index = Reactive
hyperaemia peripheral arterial tonometry index. SDMA= Symmetric
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thus the availability of L-arginine to NOS within endothelial cells)
does not change over time. The mechanism behind the change in
ADMA over time cannot be determined from these data, however
there are several possibilities. Protein catabolism in patients with
sepsis could lead to progressive release of methylated L-arginine
residues into the plasma. However, this is unlikely to be the case
because endogenous leucine flux (a measure of protein catabolism)
does not correlate with plasma ADMA concentrations in septic
humans [36]. NO causes direct inhibition of dimethylarginine
dimethylaminohydrolase (DDAH) activity by S-nitrosylation of an
active cysteine residue [37]. Thus it is possible that as patients
recover from sepsis and endothelial NO bioavailability increases,
DDAH activity is inhibited, resulting in an increase in plasma
ADMA concentrations. Finally, the longitudinal inverse associa-
tion between liver function and plasma ADMA suggests that
worsening liver function due to sepsis progression, and thus
decreased metabolism of ADMA, may also explain these findings.
The disparity between ADMA concentrations in shock and
without shock may be due to different mechanisms within these
two states. Early sepsis is a hyperdynamic state, with increased
cardiac output and liver and kidney blood flow [38,39]. This may
lead to increased degradation of ADMA in the liver by DDAH
and, to a lesser extent, increased renal excretion. This hypothesis is
supported by a study which found that the liver fractional
extraction rate for ADMA is significantly higher and circulating
ADMA is significantly lower in endotoxemic rats compared to
controls [40]. Patients with septic shock have generally developed
multiple organ failure and down-regulation of cellular functions
[41] and thus hepatic metabolism and renal excretion of ADMA
may drop back to baseline concentrations. This hypothesis is
supported by our finding that ADMA concentrations inversely
correlate with liver function, both at baseline and longitudinally.
Similar findings have recently been reported in patients with
malaria, in whom plasma ADMA concentrations were raised in
those with severe malaria but low normal in those with moderately
severe malaria [32].
Our study helps to clarify the inconsistencies reported in
previous clinical studies measuring ADMA in acute infections. It
demonstrates that while patients with septic shock have increased
ADMA, patients without shock have decreased ADMA resulting
in no significant difference between the ADMA concentrations in
pooled sepsis and hospital controls – a potentially misleading
finding unless patients are stratified by sepsis severity. The
previous studies that found that ADMA was increased in sepsis
[18,20,21] primarily enrolled patients with septic shock. The only
other published study to enrol sepsis patients without shock also
found no overall difference in plasma ADMA concentrations
between sepsis and control patients [19]; however, they did not
consider patients with and without shock separately.
This study has several limitations. Although it is at least 50%
dependant on endothelial NO [22], peripheral arterial tonometry
is not a direct measure of NO activity. Other factors are likely to
contribute to endothelial NO bioavailability in addition to the L-
arginine:ADMA ratio, including CAT transport inhibitors (such as
SDMA) and oxidative stress resulting in NO-quenching. The 67
sepsis patients were not all followed up on day 2-4, largely because
of hospital discharge; thus the longitudinal results may underes-
timate the degree of improvement in microvascular and organ
function.
Raised plasma ADMA concentrations are a strong predictor of
death in patients with sepsis and thus may be useful as a prognostic
marker. Impaired endothelial and microvascular function due to
decreased endothelial NO production may be a mechanism
linking ADMA with organ dysfunction and mortality. The
DDAH-ADMA axis is a potential therapeutic target and may be
important in individual tailoring of therapy. Agents which
compete with ADMA for NOS (such as L-arginine) or which
potentiate DDAH activity should be further investigated in sepsis.
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